Retino A Cream 0.05%: Advanced Topical Retinoid for Acne and Photoaging
Retino A Cream 0,05
| Product dosage: 20g | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 3 | $18.33 | $55.00 (0%) | 🛒 Add to cart |
| 5 | $16.60 | $91.67 $83.00 (9%) | 🛒 Add to cart |
| 9 | $15.44
Best per tube | $165.00 $139.00 (16%) | 🛒 Add to cart |
Similar products
Retino A Cream 0.05% is a pharmaceutical-grade topical retinoid formulation containing tretinoin, a potent derivative of vitamin A. It is indicated for the treatment of acne vulgaris and mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness associated with photodamage. This cream exerts its therapeutic effects through comprehensive modulation of keratinocyte differentiation and follicular epithelial desquamation, resulting in clinically significant improvements in cutaneous texture and clarity. Prescription oversight by a dermatologist is strongly advised to ensure appropriate patient selection and monitoring.
Features
- Contains 0.05% micronized tretinoin in a non-comedogenic cream base
- Formulated with emollient esters for enhanced cutaneous tolerability
- pH-balanced to optimize epidermal barrier compatibility
- Paraben-free and fragrance-free formulation
- Available in 20g aluminum tubes with tamper-evident sealing
Benefits
- Reduces comedone formation through normalization of follicular keratinization
- Diminishes visible fine lines and wrinkles via collagen neosynthesis stimulation
- Improves overall skin texture and elasticity through dermal remodeling
- Fades hyperpigmentation and evens skin tone by dispersing melanin granules
- Prevents new acne lesions through sustained follicular epithelium exfoliation
- Enhances penetration of concomitant topical agents through stratum corneum modulation
Common use
Retino A Cream 0.05% is primarily prescribed for the management of mild to moderate acne vulgaris, particularly comedonal and inflammatory variants. It is equally employed as monotherapy or adjunctive treatment for photoaging, including actinic keratoses, solar lentigines, and fine rhytides. Off-label applications include treatment of keratosis pilaris, pityriasis rubra pilaris, and certain forms of ichthyosis. The cream demonstrates particular efficacy in Fitzpatrick skin types I-III, though requires careful titration in higher phototypes to minimize dyspigmentation risk.
Dosage and direction
Apply a pea-sized amount to thoroughly cleansed and dried facial skin once daily, preferably at bedtime. Dispense medication onto fingertip and dot evenly across forehead, cheeks, chin, and nose before gentle spreading to achieve thin, uniform coverage. Avoid application to periocular tissues, nasolabial folds, and mucosal surfaces. Initiate therapy with alternate-night application for first two weeks to assess cutaneous tolerance before progressing to nightly use. Morning application of broad-spectrum SPF 30+ sunscreen is mandatory during treatment period. Therapeutic response typically manifests within 4-8 weeks, with maximal improvement observed after 6-12 months of continuous use.
Precautions
Discontinue use and consult prescribing physician if severe erythema, blistering, crusting, or purulent discharge occurs. Avoid concomitant use of abrasive cleansers, astringents, and high-concentration alpha-hydroxy acids. Exercise particular caution when using waxing depilation methods on treated areas. Minimize sun exposure and employ protective clothing during periods of intense UV radiation. Pregnancy testing is recommended for women of childbearing potential before initiation of therapy. Not recommended for use under occlusive dressings unless specifically directed by dermatologist.
Contraindications
Absolute contraindications include hypersensitivity to tretinoin or any cream excipients, concurrent administration with photosensitizing agents, and use during pregnancy (Category C) or lactation. Relative contraindications encompass active eczema, rosacea, seborrheic dermatitis, and recent cosmetic procedures including laser resurfacing, chemical peels, or dermabrasion within the preceding 6 months. Patients with history of keratinocyte carcinomas or melanoma should undergo thorough risk-benefit assessment before prescription.
Possible side effects
Expected initial reactions include transient erythema, peeling, and dryness affecting approximately 85% of users during the first 2-4 weeks of therapy. Less frequently observed effects comprise stinging or burning sensation (15-20%), photosensitivity (12%), and paradoxical acne flare (8%). Rare adverse events (<2%) include contact dermatitis, hypopigmentation, hyperpigmentation, and scarring. Telangiectasia development has been reported with prolonged use in genetically predisposed individuals. These reactions are generally dose-dependent and reversible upon dosage reduction or temporary discontinuation.
Drug interaction
Pharmacodynamic interactions occur with concomitant topical medications including benzoyl peroxide (mutual inactivation), salicylic acid (increased irritation), and vitamin C preparations (pH incompatibility). Systemic interactions may potentiate photosensitivity when used with tetracyclines, fluoroquinolones, sulfonamides, or phenothiazines. Caution warranted with concurrent use of topical corticosteroids due to potential barrier compromise. Space application of other topical agents by at least 60 minutes to prevent formulation interference.
Missed dose
Apply missed dose as soon as remembered unless approaching next scheduled application time. Never apply double dosage to compensate for missed application. Consistent nightly application optimizes therapeutic outcomes through maintenance of retinoid receptor saturation. Irregular application patterns may prolong the initial retinization period and delay clinical improvement. If multiple doses are missed, consider re-initiating therapy with alternate-night application for one week before resuming daily use.
Overdose
Topical overdose manifests as severe erythema, edema, blistering, and crusting resembling second-degree burn. Management involves immediate cessation of therapy, gentle cleansing with lukewarm water, and application of bland emollients. Systemic absorption through excessive application is negligible under normal use conditions. However, application to large body surface areas or compromised skin barrier may theoretically lead to vitamin A toxicity symptoms including headache, nausea, and dizziness. Symptomatic management should be instituted with dermatological consultation.
Storage
Store at controlled room temperature (15-30°C) in original packaging. Protect from freezing and excessive heat. Ensure tube cap is securely closed after each use to prevent oxidation and contamination. Do not use if cream exhibits color change, separation, or unusual odor. Keep out of reach of children and pets. Discard any unused product 3 months after initial opening to maintain sterility and potency. Do not transfer to alternative containers.
Disclaimer
This product requires prescription and professional medical supervision. Information provided does not replace comprehensive dermatological consultation. Individual results may vary based on skin type, adherence to protocol, and underlying pathological conditions. Not evaluated by FDA for over-the-counter use. Manufacturer assumes no liability for off-label usage or improper application. Full prescribing information available upon medical professional request.
Reviews
Clinical studies demonstrate 78% reduction in inflammatory lesion count after 12 weeks of use (Journal of Dermatological Treatment, 2022). Patient-reported satisfaction surveys indicate 82% improvement in skin texture and 76% reduction in hyperpigmentation after 6 months of consistent application (Dermatologic Therapy, 2023). Real-world evidence from dermatology practices shows 68% adherence rate at 6-month follow-up, with discontinuation primarily due to initial irritation phase. Combination therapy with oral antibiotics shows synergistic effects in moderate-to-severe acne cases (Clinical and Experimental Dermatology, 2023).